Prescription ·Strong evidence ·Reviewed May 2026
Dulaglutide is a once-weekly injectable GLP-1 receptor agonist for type 2 diabetes. The REWIND trial uniquely demonstrated cardiovascular benefit in a broader diabetes population, including patients without established cardiovascular disease. Its ready-to-use single-dose pen has contributed to high patient satisfaction and adherence.
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 0.7–1.6%, cardiovascular event reduction (rewind: 12% rrr for mace), weight loss (1.5–5 kg). 10 sources indexed (2021–2025), with 5 interaction records on file.
Core mechanism
A GLP-1 receptor agonist consisting of a modified GLP-1 analogue covalently linked to a modified Fc fragment of human IgG4, which slows clearance and extends the half-life to approximately 5 days. Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.8
Inject subcutaneously in abdomen, thigh, or upper arm on the same day each week. Can be given at any time, with or without meals.2
Dulaglutide and berberine both lower glucose through different pathways. Combined GI side effects and hypoglycemia risk are the main concerns.
Recommendation: Same precautions as other GLP-1 agonists. Monitor glucose and watch for excessive GI symptoms.
Dulaglutide is a weekly GLP-1 receptor agonist that lowers glucose by stimulating glucose-dependent insulin secretion and slowing gastric emptying. Chromium improves insulin sensitivity. On dulaglutide alone the hypoglycemia risk is low, but additive effects can produce symptomatic lows when chromium is added to a regimen that also includes insulin or a sulfonylurea.
Recommendation: If dulaglutide is your only diabetes medication, chromium can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether those agents need to be reduced first.
Alpha-lipoic acid improves insulin sensitivity and dulaglutide augments glucose-dependent insulin release. On dulaglutide alone the hypoglycemia risk is low, but additive effects can matter when ALA is added on top of insulin or a sulfonylurea. ALA has also rarely triggered insulin autoimmune syndrome with severe spontaneous hypoglycemia.
Recommendation: If dulaglutide is your only diabetes medication, ALA can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether the other agent needs a dose reduction first.
Dulaglutide commonly causes nausea, especially during dose titration. Ginger reduces nausea in pregnancy, postoperative, and chemotherapy-induced nausea meta-analyses. Combined with dulaglutide, ginger can reduce GLP-1 nausea without affecting glycemic efficacy.
Recommendation: If dulaglutide nausea is a problem, ginger 1-2 g/day (capsules or tea) is a reasonable adjunct. Take it with meals. If you are also on warfarin or another anticoagulant, discuss with your prescriber first.
Psyllium husk reduces postprandial glucose and HbA1c in type 2 diabetes by slowing carbohydrate absorption. Dulaglutide also slows gastric emptying and lowers postprandial glucose. The combination reduces postprandial spikes without driving hypoglycemia, though additive GI slowing can intensify bloating or early satiety. Dulaglutide is injected so psyllium's drug-binding does not apply.
Recommendation: Psyllium (5-10 g/day, split with meals) is a reasonable adjunct on dulaglutide. Drink plenty of water and increase the dose gradually to limit bloating. Separate psyllium from any oral medications by at least 2-4 hours.
Numbered references. Citations throughout the page link here.
Karimi MA, Gholami Chahkand MS, Dadkhah PA et al.. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. Frontiers in pharmacology. 2025
Billings LK, Winne L, Sharma P et al.. Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Annals of internal medicine. 2025
Takahashi Y, Nomoto H, Yokoyama H et al.. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study). Diabetes, obesity & metabolism. 2023
Zhang Y, Qu Z, Lu T et al.. Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients. 2023
Frias JP, Bonora E, Nevarez Ruiz L et al.. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes care. 2021
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack